Search

Your search keyword '"Gonzalez, Graciela"' showing total 555 results
Start Over Author "Gonzalez, Graciela" Language english
555 results on '"Gonzalez, Graciela"'

5. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Author

Short, Nicholas J., Ong, Faustine, Ravandi, Farhad, Nogueras-Gonzalez, Graciela, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Borthakur, Gautam, Oran, Betul, Al-Atrash, Gheath, Mehta, Rohtesh, Jabbour, Elias J., Yilmaz, Musa, Issa, Ghayas C, Maiti, Abhishek, Champlin, Richard E, Kantarjian, Hagop, Shpall, Elizabeth J, and Popat, Uday

Published
2023
Full Text
View/download PDF

9. Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection

Author

Rooney, Michael K., De, Brian, Corrigan, Kelsey, Smith, Grace L., Taniguchi, Cullen, Minsky, Bruce D., Ludmir, Ethan B., Koay, Eugene J., Das, Prajnan, Koong, Albert C., Peacock, Oliver, Chang, George, You, Y. Nancy, Morris, Van K., Nogueras-González, Graciela, and Holliday, Emma B.

Published
2023
Full Text
View/download PDF

10. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

12. Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy

Author

De, Brian, Corrigan, Kelsey L., Rooney, Michael K., Ludmir, Ethan B., Das, Prajnan, Smith, Grace L., Taniguchi, Cullen M., Minsky, Bruce D., Koay, Eugene J., Koong, Albert, Morris, Van K., Messick, Craig A., You, Y. Nancy, Chang, George J., Westney, O. Lenaine, Nogueras Gonzalez, Graciela M., and Holliday, Emma B.

Published
2022
Full Text
View/download PDF

17. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

Author

Vo, Henry Hiep, Fu, Siqing, Hong, David S., Karp, Daniel D., Piha-Paul, Sarina, Subbiah, Vivek, Janku, Filip, Naing, Aung, Yap, Timothy A., Rodon, Jordi, Ajani, Jaffer A., Cartwright, Carrie, Johnson, Amber, Song, I-Wen, Beck, Jennifer, Kahle, Michael, Nogueras-Gonzalez, Graciela M., Miller, Vincent, Chao, Calvin, Vining, David J., Berry, Donald A., Meric-Bernstam, Funda, and Tsimberidou, Apostolia-Maria

Published
2022
Full Text
View/download PDF

18. Exploring the factors that affect the otucomes of a genre-based approach to listening

Author

Arizmendi Gonzalez, Graciela, Zotzmann, Karin, and Wright, Vicky

Subjects
428.2
Abstract

The aim of this research is to explore the factors that affect listeners when they are introduced to the generic features of texts. In this intervention study, learners in a Mexican university are introduced to the linguistic features, generic structure and context of spoken narrative texts about a film, in the first and foreign language (L1) and (L2), in order to better understand the development of L2 listening skills. On the basis of participants’ stimulated recalls (SR) and semi-structured interviews, I analysed the listeners’ thought processes and listening strategies, after they are introduced to the generic features of narratives. While initially set up as experimental study with an experimental (EG) and a control group (CG), the qualitative data reveals that different listeners’ in both groups used different listening cognitive, metacognitive, affective and sociocultural strategies, during the intervention. The participants in this study are 34 undergraduates studying for an English language teaching degree. Seventeen students are enrolled in the fourth semester and take part in the CG and another seventeen in the EG. The CG attended a regular class, whereas the EG received instruction from a genre-based approach for listening purposes in a scaffolded way, going from guided deconstruction to independent reconstruction of spoken narratives. Participants analyse the texts’ social and textual elements including the context, language used, variations and organisation. The findings show that listening at a discourse level is multidimensional. Participants in the EG elaborate and incorporate different types of prior knowledge. While listening, they attempt to identify and contextualize social situations as well as structural elements based on knowledge gained through a genre-based approach. Findings unveil aspects affecting the outcomes of a genre based approach in listening and can help researchers appreciate the practicality of these findings for the understanding of listening from a genre-based perspective.

Published
2018

19. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Author

Wang, Michael L, Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Nastoupil, Loretta, Fayad, Luis, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hill, Holly A, Yao, Yixin, Hagemeister, Fredrick B, Westin, Jason R, Fowler, Nathan, Samaniego, Felipe, Steiner, Raphael, Nair, Ranjit, Iyer, Swaminathan P, Navsaria, Lucy, Badillo, Maria, Feng, Lei, Xuelin, Huang, Nogueras Gonzalez, Graciela M, Xu, Guofan, Wagner-Bartak, Nicolaus, Thirumurthi, Selvi, Santos, David, Tang, Guilin, Lin, Pei, Wang, Sa A, Jorgensen, Jeff, Yin, C Cameron, Li, Shaoying, Patel, Keyur P, Vega, Francisco, Medeiros, L Jeffery, Flowers, Christopher R, and Wang, Linghua

Published
2022
Full Text
View/download PDF

22. Cardiac rehabilitation availability and characteristics in Latin America and the Caribbean: A Global Comparison

Author

Chacin-Suarez, Audry, Grace, Sherry L., Anchique-Santos, Claudia, Supervia, Marta, Turk-Adawi, Karam, Britto, Raquel R., Scantlebury, Dawn C., Araya-Ramirez, Felipe, Gonzalez, Graciela, Benaim, Briseida, Fernandez, Rosalia, Hol, Jacqueline, Burdiat, Gerard, Salmon, Richard, Lomeli, Hermes, Mamataz, Taslima, Medina-Inojosa, Jose R., and Lopez-Jimenez, Francisco

Published
2021
Full Text
View/download PDF

28. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy.

Author

Contieri, Roberto, Tan, Wei Shen, Grajales, Valentina, Hensley, Patrick J., Martini, Alberto, Bree, Kelly, Myers, Amanda, Nogueras‐Gonzalez, Graciela, Navai, Neema, Dinney, Colin P., Guo, Charles, and Kamat, Ashish M.

Subjects
NON-muscle invasive bladder cancer, ILEAL conduit surgery, BCG immunotherapy, INTRAVESICAL administration, CYSTECTOMY, OVERALL survival, PROGRESSION-free survival, UROTHELIUM
Abstract

Objective: To evaluate the prognostic value of T1 substaging in patients treated with bacillus Calmette‐Guérin (BCG) or immediate radical cystectomy (iRC). Materials and Methods: We performed an institutional review board‐approved retrospective study analysing non‐muscle‐invasive bladder cancer (NMIBC) patients with pT1 disease treated with either BCG or iRC between 2000 and 2020. Lamina propria (LP) invasion characteristics were extracted from the pathology report. The Kaplan–Meier method was used to calculate overall survival (OS), cancer‐specific survival (CSS) and metastasis‐free survival (MFS). Multivariable Cox models were used to determine the association between progression‐free survival (PFS) and characteristics in the BCG cohort. A logistic regression model explored the relationship between T1 substaging and upstaging to >pT2 at iRC. Results: A total of 411 T1 high‐grade patients were identified. LP invasion characteristics were as follows: not specified: 115 (28%); focal/superficial (F/S): 147 (35.8%); and extensive/multifocal (E/M): 149 (36.2%). Overall, 303 patients (73.7%) received BCG, and 108 patients (26.3%) underwent iRC. The median (interquartile range) follow‐up was 53 (32–96) months. Patients with E/M LP invasion were significantly more likely to undergo iRC (34% vs. 19%; P = 0.003). Patients with E/M LP invasion showed poorer MFS and CSS compared to those with F/S LP invasion when treated with BCG but not when treated with iRC. Among BCG‐treated patients, progression occurred in 41 patients and E/M LP invasion was independently associated with progression after BCG (hazard ratio 5.3, 95% confidence interval [CI] 2.2–13.1; P < 0.001). T1 substaging was not associated with upstaging at RC (odds ratio 3.15, 95% CI 0.82–12.12; P = 0.095). Conclusions: Extensive/multifocal LP invasion was associated with poor PFS, MFS and CSS in patients treated with BCG. T1 substaging provides valuable prognostic information and should be reported in pathology reports. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study.

Author

Sewastjanow-Silva, Matheus, Xiao, Lianchun, Gonzalez, Graciela N., Wang, Xuemei, Hofstetter, Wayne, Swisher, Stephen, Mehran, Reza, Sepesi, Boris, Bhutani, Manoop S., Weston, Brian, Coronel, Emmanuel, Waters, Rebecca E., Rogers, Jane E., Smith, Jackie, Lyons, Larry, Reilly, Norelle, Yao, James C., Ajani, Jaffer A., and Murphy, Mariela Blum

Subjects
ADENOCARCINOMA, PATIENT safety, RESEARCH funding, CLINICAL trials, ESOPHAGEAL tumors, TREATMENT effectiveness, DESCRIPTIVE statistics, CANCER chemotherapy, MONOCLONAL antibodies, LONGITUDINAL method, KAPLAN-Meier estimator, COMBINED modality therapy, DRUG efficacy, OXALIPLATIN, FLUOROURACIL, DATA analysis software, CONFIDENCE intervals, TIME, OVERALL survival, PHARMACODYNAMICS
Abstract

Simple Summary: What is the efficacy and safety of atezolizumab with oxaliplatin and 5-fluorouracil followed by atezolizumab for localized esophageal or gastroesophageal junction adenocarcinomas before surgical resection? In this non-randomized controlled clinical trial, the observed pathological complete response (downstaging to ypT0N0M0) after surgery was 11.1%. The median overall survival was 38.6 months, and the median disease-free survival was 28.8 months. Two patients had grade 4 treatment-related adverse events. These findings suggest that atezolizumab with oxaliplatin and 5-fluorouracil for the treatment of localized, resectable adenocarcinoma of the esophagus or gastroesophageal junction showed moderate efficacy with an acceptable safety profile and warrants further investigation. Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall survival (OS). Building on the recent evidence that PD-1 inhibition plus chemotherapy improves the OS of patients with metastatic GEJ adenocarcinoma, we evaluated whether the application of this strategy in the neoadjuvant setting would improve the pathological response. This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab. The primary objective goal was to achieve 20% pathCR. From the twenty enrolled patients, eighteen underwent resection and two (10%, 95% CI: 1.24–31.7%) achieved pathCR. After a median follow-up duration of 40.7 months, 11 patients had disease recurrence and 10 had died. The median disease-free and OS were 28.8 (95% CI: 14.7, NA) and 38.6 months (95% CI: 30.5, NA), respectively. No treatment-related adverse events led to death. Although modified FOLFOX plus atezolizumab did not achieve the expected pathCR, an acceptable safety profile was observed. Our results support the continued development of a more refined strategy (neoadjuvant chemotherapy plus perioperative immunotherapy/targeted agents) with molecular/immune profiling in parallel. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Author

Bose, Prithviraj, Verstovsek, Srdan, Cortes, Jorge E., Tse, Susan, Gasior, Yvonne, Jain, Nitin, Jabbour, Elias J., Estrov, Zeev, Alvarado, Yesid, DiNardo, Courtney D., Pemmaraju, Naveen, Kornblau, Steven M., Kadia, Tapan M., Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Masarova, Lucia, Villareal, John, Pierce, Sherry A., Nogueras-Gonzalez, Graciela, Huang, Xuelin, Garcia-Manero, Guillermo, Kantarjian, Hagop M., and Ravandi, Farhad

Published
2020
Full Text
View/download PDF

32. Nature of Cardiac Rehabilitation Around the Globe

Author

Supervia, Marta, Turk-Adawi, Karam, Lopez-Jimenez, Francisco, Pesah, Ella, Ding, Rongjing, Britto, Raquel R., Bjarnason-Wehrens, Birna, Derman, Wayne, Abreu, Ana, Babu, Abraham S., Santos, Claudia Anchique, Jong, Seng K., Cuenza, Lucky, Yeo, Tee Joo, Scantlebury, Dawn, Andersen, Karl, Gonzalez, Graciela, Giga, Vojislav, Vulic, Dusko, Vataman, Eleonora, Cliff, Jacqueline, Kouidi, Evangelia, Yagci, Ilker, Kim, Chul, Benaim, Briseida, Estany, Eduardo Rivas, Fernandez, Rosalia, Radi, Basuni, Gaita, Dan, Simon, Attila, Chen, Ssu-Yuan, Roxburgh, Brendon, Martin, Juan Castillo, Maskhulia, Lela, Burdiat, Gerard, Salmon, Richard, Lomelí, Hermes, Sadeghi, Masoumeh, Sovova, Eliska, Hautala, Arto, Tamuleviciute-Prasciene, Egle, Ambrosetti, Marco, Neubeck, Lis, Asher, Elad, Kemps, Hareld, Eysymontt, Zbigniew, Farsky, Stefan, Hayward, Jo, Prescott, Eva, Dawkes, Susan, Santibanez, Claudio, Zeballos, Cecilia, Pavy, Bruno, Kiessling, Anna, Sarrafzadegan, Nizal, Baer, Carolyn, Thomas, Randal, Hu, Dayi, and Grace, Sherry L.

Published
2019
Full Text
View/download PDF

33. Cardiac Rehabilitation Availability and Density around the Globe

Author

Turk-Adawi, Karam, Supervia, Marta, Lopez-Jimenez, Francisco, Pesah, Ella, Ding, Rongjing, Britto, Raquel R., Bjarnason-Wehrens, Birna, Derman, Wayne, Abreu, Ana, Babu, Abraham S., Santos, Claudia Anchique, Jong, Seng Khiong, Cuenza, Lucky, Yeo, Tee Joo, Scantlebury, Dawn, Andersen, Karl, Gonzalez, Graciela, Giga, Vojislav, Vulic, Dusko, Vataman, Eleonora, Cliff, Jacqueline, Kouidi, Evangelia, Yagci, Ilker, Kim, Chul, Benaim, Briseida, Estany, Eduardo Rivas, Fernandez, Rosalia, Radi, Basuni, Gaita, Dan, Simon, Attila, Chen, Ssu-Yuan, Roxburgh, Brendon, Martin, Juan Castillo, Maskhulia, Lela, Burdiat, Gerard, Salmon, Richard, Lomelí, Hermes, Sadeghi, Masoumeh, Sovova, Eliska, Hautala, Arto, Tamuleviciute-Prasciene, Egle, Ambrosetti, Marco, Neubeck, Lis, Asher, Elad, Kemps, Hareld, Eysymontt, Zbigniew, Farsky, Stefan, Hayward, Jo, Prescott, Eva, Dawkes, Susan, Santibanez, Claudio, Zeballos, Cecilia, Pavy, Bruno, Kiessling, Anna, Sarrafzadegan, Nizal, Baer, Carolyn, Thomas, Randal, Hu, Dayi, and Grace, Sherry L.

Published
2019
Full Text
View/download PDF

38. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Author

Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O'Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, and Keating, Michael J.

Published
2019
Full Text
View/download PDF

40. Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials.

Author

Srivastava, Akanksha, Nogueras-Gonzalez, Graciela M., Yimin Geng, Singh, Jasdev, Myers, Jeffrey N., Yisheng Li, and Chambers, Mark S.

Subjects
*CANCER treatment, *IMMUNE checkpoint inhibitors, *ADVERSE health care events, *CLINICAL trials, *DATA extraction
Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, their oral toxicity profile is not well elucidated. This review aimed to investigate the prevalence of oral toxicities including xerostomia, mucositis/stomatitis, dysgeusia, dysphagia, oral/oropharyngeal pain, oral infections, angular cheilitis, osteonecrosis, osteomyelitis, and oral mucosal reactions with ICIs. A review protocol was registered with PROSPERO (ID: CRD42023391674). A systematic search of ClinicalTrials.gov was conducted as of April 10, 2022. Studies were selected, assessed, and data extracted using PRISMA guidelines. Oral toxicity data were extracted from study arms using a single immunotherapy drug. Meta-analyses were conducted to summarize prevalence of oral toxicities using random-effects models. Of 750 screened records, 95 trials were included in the meta-analysis with published results. Time between study completion and first publication on ClinicalTrials.gov was 1 to 146 months (mean = 20.3, SD = 18.4). Weighted pooled prevalence was 5% (95% CI: 4-6%) for xerostomia, 3% (95% CI: 3-4%) for mucositis/stomatitis, 3% (95% CI: 2-3%) for dysgeusia, 2% (95% CI: 1-2%) for dysphagia, 3% (95% CI: 2-4%) for oropharyngeal/oral pain, 2% (95% CI: 1-3%) for oral candidiasis, and 2% (95% CI: 0-4%) for angular cheilitis. Subgroup differences based on ICI drugs were minimal. No trials reported lichenoid or pemphigoid mucosal reactions. Meta-analysis results revealed low prevalence of oral toxicities with ICIs; however, data reporting was limited and inconsistent. Limitations of study dataset reveal a significant need for systematic collection of oral morbidity data as well as improved consistency and compliance of reporting results on ClinicalTrials.gov. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin.

Author

Contieri, Roberto, Grajales, Valentina, Tan, Wei Shen, Martini, Alberto, Sood, Akshay, Hensley, Patrick, Bree, Kelly, Lobo, Niyati, Nogueras‐Gonzalez, Graciela M., Guo, Charles C., Navai, Neema, Dinney, Colin P., and Kamat, Ashish M.

Subjects
NON-muscle invasive bladder cancer, BCG immunotherapy, CANCER patients, INTRAVESICAL administration, TREATMENT effectiveness
Abstract

Objective: To evaluate the impact of age on oncological outcomes in a large contemporary cohort of patients with non‐muscle‐invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette–Guérin (BCG). Patients and Methods: We performed an Institutional Review Board‐approved retrospective study analysing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020. Adequate BCG was defined as per United States Food and Drug Administration (FDA) guidelines as being receipt of at least five of six induction BCG instillations with a minimum of two additional doses (of planned maintenance or of re‐induction) of BCG instillations within a span of 6 months. The study's primary outcome was to determine if age >70 years was associated with progression to MIBC cancer or distant metastasis. The cumulative incidence method and the competing‐risk regression analyses were used to investigate the association of advanced age (>70 years) with progression, high‐grade (HG) recurrence and cancer‐specific mortality (CSM). Results: Overall, data from 632 patients were analysed: 355 patients (56.2%) were aged ≤70 years and 277 (43.8%) were >70 years. Age >70 years did not adversely affect either cumulative incidence of progression or HG recurrence (P = 0.067 and P = 0.644, respectively). On competing‐risk regression analyses, age >70 years did not emerge as an independent predictor of progression or HG recurrence (sub‐standardised hazard ratio [SHR] 1.57, 95% confidence interval [CI] 0.87–2.81, P = 0.134; and SHR 1.05, 95% CI 0.77–1.44, P = 0.749). Not unexpectedly, patients in the older group did have higher overall mortality (P < 0.001) but not CSM (P = 0.057). Conclusion: Age >70 years was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. BCG should not be withheld from older patients seeking for bladder sparing options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Benchmarking of the 2010 BioCreative Challenge III text-mining competition by the BioGRID and MINT interaction databases

Author

Krallinger, Martin, Vazquez, Miguel, Leitner, Florian, Salgado, David, Chatr-aryamontri, Andrew, Winter, Andrew, Perfetto, Livia, Briganti, Leonardo, Licata, Luana, Iannuccelli, Marta, Castagnoli, Luisa, Cesareni, Gianni, Tyers, Mike, Schneider, Gerold, Rinaldi, Fabio, Leaman, Robert, Gonzalez, Graciela, Matos, Sergio, Kim, Sun, Wilbur, W, Rocha, Luis, Shatkay, Hagit, Tendulkar, Ashish V, Agarwal, Shashank, Liu, Feifan, Wang, Xinglong, Rak, Rafal, Noto, Keith, Elkan, Charles, Lu, Zhiyong, Dogan, Rezarta, Fontaine, Jean-Fred, Andrade-Navarro, Miguel A, and Valencia, Alfonso

Abstract

Abstract Background Determining usefulness of biomedical text mining systems requires realistic task definition and data selection criteria without artificial constraints, measuring performance aspects that go beyond traditional metrics. The BioCreative III Protein-Protein Interaction (PPI) tasks were motivated by such considerations, trying to address aspects including how the end user would oversee the generated output, for instance by providing ranked results, textual evidence for human interpretation or measuring time savings by using automated systems. Detecting articles describing complex biological events like PPIs was addressed in the Article Classification Task (ACT), where participants were asked to implement tools for detecting PPI-describing abstracts. Therefore the BCIII-ACT corpus was provided, which includes a training, development and test set of over 12,000 PPI relevant and non-relevant PubMed abstracts labeled manually by domain experts and recording also the human classification times. The Interaction Method Task (IMT) went beyond abstracts and required mining for associations between more than 3,500 full text articles and interaction detection method ontology concepts that had been applied to detect the PPIs reported in them. Results A total of 11 teams participated in at least one of the two PPI tasks (10 in ACT and 8 in the IMT) and a total of 62 persons were involved either as participants or in preparing data sets/evaluating these tasks. Per task, each team was allowed to submit five runs offline and another five online via the BioCreative Meta-Server. From the 52 runs submitted for the ACT, the highest Matthew's Correlation Coefficient (MCC) score measured was 0.55 at an accuracy of 89% and the best AUC iP/R was 68%. Most ACT teams explored machine learning methods, some of them also used lexical resources like MeSH terms, PSI-MI concepts or particular lists of verbs and nouns, some integrated NER approaches. For the IMT, a total of 42 runs were evaluated by comparing systems against manually generated annotations done by curators from the BioGRID and MINT databases. The highest AUC iP/R achieved by any run was 53%, the best MCC score 0.55. In case of competitive systems with an acceptable recall (above 35%) the macro-averaged precision ranged between 50% and 80%, with a maximum F-Score of 55%. Conclusions The results of the ACT task of BioCreative III indicate that classification of large unbalanced article collections reflecting the real class imbalance is still challenging. Nevertheless, text-mining tools that report ranked lists of relevant articles for manual selection can potentially reduce the time needed to identify half of the relevant articles to less than 1/4 of the time when compared to unranked results. Detecting associations between full text articles and interaction detection method PSI-MI terms (IMT) is more difficult than might be anticipated. This is due to the variability of method term mentions, errors resulting from pre-processing of articles provided as PDF files, and the heterogeneity and different granularity of method term concepts encountered in the ontology. However, combining the sophisticated techniques developed by the participants with supporting evidence strings derived from the articles for human interpretation could result in practical modules for biological annotation workflows.

Published
2011

50. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

Author

Jain, Preetesh, Keating, Michael, Renner, Sarah, Cleeland, Charles, Xuelin, Huang, Gonzalez, Graciela Nogueras, Harris, David, Li, Ping, Liu, Zhiming, Veletic, Ivo, Rozovski, Uri, Jain, Nitin, Thompson, Phillip, Bose, Prithviraj, DiNardo, Courtney, Ferrajoli, Alessandra, O'Brien, Susan, Burger, Jan, Wierda, William, Verstovsek, Srdan, Kantarjian, Hagop, and Estrov, Zeev

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results